Your session is about to expire
← Back to Search
Immunotherapy Combinations for Lung Cancer (ARC-4 Trial)
ARC-4 Trial Summary
This trial is testing a new cancer drug to see if it is safe and effective. The drug will be given with or without another drug that is already approved to treat cancer.
ARC-4 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowARC-4 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ARC-4 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a recent tissue sample from my tumor, not older than 24 months.My organs and bone marrow are working well.I have not taken any medications that could interact with etrumadenant.I haven't taken strong CYP3A4 affecting drugs in the last 4 weeks or 5 half-lives.I haven't needed systemic treatment for an autoimmune disease in the last 2 years, except for vitiligo or childhood asthma.I haven't received any treatment for my condition and I refuse standard therapy.I haven't had active cancer in the last 2 years, except for certain curable types.I have a genetic change in my cancer and have tried all targeted treatments available to me, but I haven't had chemotherapy or PD-1/-L1 therapy.My cancer progressed after PD-1/-L1 therapy and I've had less than 4 cycles of carboplatin/pemetrexed.I haven't taken certain oral medications that affect cancer resistance within the last 4 weeks or 5 half-lives of the drug.I have not been treated for my condition and I refuse standard therapy.I have a genetic mutation in my cancer and have tried all targeted treatments available to me, but I haven't had chemotherapy or PD-1/PD-L1 therapy.It's been over 4 weeks since my last experimental treatment.I have previously used medication that targets the adenosine pathway.I haven't taken any TKI therapy in the last 5 days.My cancer has worsened despite PD-1/-L1 therapy and I haven't had chemotherapy.I am 18 years old or older.My lung cancer is not squamous, has spread, and is getting worse.I have not received any live vaccines in the last 4 weeks.I've had treatments before and now have no other options for a cure.You need to have at least one noticeable tumor that can be measured according to specific guidelines.I am fully active or can carry out light work.I have tried many treatments and have no other options for a cure.My cancer has a specific mutation and didn't respond well to certain treatments.
- Group 1: Dose Expansion Arm 1
- Group 2: Dose Escalation Arm B
- Group 3: Dose Expansion Arm 2
- Group 4: Dose Escalation Arm A
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any open vacancies for this research project?
"Clinicaltrials.gov doesn't display any new data suggesting that this trial is recruiting at the moment--it was initially posted on April 1st 2019 and last updated November 7th 2022. There are, however, 3643 other trials actively seeking participants right now."
To what extent can Etrumadenant pose a hazard to individuals receiving treatment?
"The safety of Etrumadenant was rated a 1, as this is an early stage trial with minimal data confirming its efficacy and protection."
What is the aggregate amount of individuals who are taking part in this research trial?
"At this time, no further candidates are required for the trial which was originally posted on April 1st 2019 and last edited November 7th 2022. There is a wealth of other studies looking for participants with lung cancer (2047) or Etrumadent (1596) currently recruiting."
What medical applications does Etrumadenant typically have?
"Etrumadenant is commonly used to combat malignant neoplasms, but also can be efficacious for managing unresectable melanoma, microsatellite instability high, and locally advanced nonsquamous non-small cell lung cancer."
How many distinct sites are partaking in this experimental undertaking?
"Currently, 20 medical centres are accepting patients for this investigation. Examples of these include Medical Oncology Associates in Spokane, Florida Cancer Specialists & Research Institute in Tavares and Tennessee Oncology in Nashville - as well as an additional 17 sites."
Are there any analogous studies which have used Etrumadenant in their methodology?
"Etrumadenant's initial research was conducted in the year 2002 at Bristol Royal Hospital for Children. In total, 1274 studies have been completed and 1596 are currently underway with a considerable portion of those trials taking place close to Spokane, Washington."
Share this study with friends
Copy Link
Messenger